PMID- 11988621
OWN - NLM
STAT- MEDLINE
DCOM- 20020513
LR  - 20191210
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 33
IP  - 5
DP  - 2002 May
TI  - Can transcranial ultrasonication increase recanalization flow with tissue 
      plasminogen activator?
PG  - 1399-404
AB  - BACKGROUND AND PURPOSE: In thrombolytic therapy for acute ischemic stroke, it is 
      essential to obtain rapid thrombolysis before ischemic neuronal injury occurs. To 
      develop a new technique of thrombolysis for acute ischemic stroke, the effect of 
      transcranially applied ultrasound (TUS) on thrombolysis was examined. METHODS: An 
      occlusion model of rabbit femoral artery was produced with thrombin after 
      establishment of stenotic flow and endothelial damage. After stable occlusion was 
      confirmed, monteplase (mtPA) was administered intravenously, and ultrasound (490 
      kHz, 0.13 W/cm2) was applied through a piece of temporal bone (TUS group; n=9). 
      The control group received mtPA alone (tissue plasminogen activator [tPA] group; 
      n=12). To verify the efficacy of TUS, femoral artery flow was measured during the 
      procedure. RESULTS: The recanalization ratio was 16.7% (2 of 12) in the tPA group 
      and 66.7% (6 of 9) in the TUS group. The recanalization ratio in the TUS group 
      was higher than that in the tPA group (P=0.03). Patency flow ratio, which was 
      defined as recanalization flow divided by baseline flow, of the TUS group 
      (44.6+/-13.9%) was significantly greater than that of the tPA group (9.9+/-6.8%) 
      at 60 minutes (P=0.025). Patency flow ratio became higher in the TUS group than 
      in the tPA group between 20 and 30 minutes from the start of thrombolysis. 
      CONCLUSIONS: Low-frequency and low-intensity TUS enhanced thrombolysis by mtPA in 
      a rabbit femoral artery occlusion model. This technique should be clinically 
      useful for thrombolysis in acute ischemic stroke.
FAU - Ishibashi, Toshihiro
AU  - Ishibashi T
AD  - Department of Neurosurgery, Jikei University School of Medicine, Tokyo, Japan. 
      isb@fd6.so-net.ne.jp
FAU - Akiyama, Masahiko
AU  - Akiyama M
FAU - Onoue, Hisashi
AU  - Onoue H
FAU - Abe, Toshiaki
AU  - Abe T
FAU - Furuhata, Hiroshi
AU  - Furuhata H
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Animals
MH  - Blood Flow Velocity/drug effects
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Femoral Artery/*drug effects/pathology/*physiopathology
MH  - Fibrinolytic Agents/administration & dosage
MH  - Injections, Intravenous
MH  - Plasminogen Activators/administration & dosage
MH  - Rabbits
MH  - Temperature
MH  - Thrombosis/pathology/*therapy
MH  - Time Factors
MH  - Tissue Plasminogen Activator/*administration & dosage
MH  - Treatment Outcome
MH  - Ultrasonic Therapy/*methods
MH  - Ultrasonography, Doppler, Transcranial
EDAT- 2002/05/04 10:00
MHDA- 2002/05/15 10:01
CRDT- 2002/05/04 10:00
PHST- 2002/05/04 10:00 [pubmed]
PHST- 2002/05/15 10:01 [medline]
PHST- 2002/05/04 10:00 [entrez]
AID - 10.1161/01.str.0000013789.15436.42 [doi]
PST - ppublish
SO  - Stroke. 2002 May;33(5):1399-404. doi: 10.1161/01.str.0000013789.15436.42.